CN101535300B - Iap bir域结合化合物 - Google Patents

Iap bir域结合化合物 Download PDF

Info

Publication number
CN101535300B
CN101535300B CN200780027024.4A CN200780027024A CN101535300B CN 101535300 B CN101535300 B CN 101535300B CN 200780027024 A CN200780027024 A CN 200780027024A CN 101535300 B CN101535300 B CN 101535300B
Authority
CN
China
Prior art keywords
compound
formula
compounds
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780027024.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101535300A (zh
Inventor
A·劳伦特
S·贾维斯
P·比罗
A·布德罗
J·贾奎斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aegera Therapeutics Inc
Original Assignee
Aegera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegera Therapeutics Inc filed Critical Aegera Therapeutics Inc
Publication of CN101535300A publication Critical patent/CN101535300A/zh
Application granted granted Critical
Publication of CN101535300B publication Critical patent/CN101535300B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
CN200780027024.4A 2006-05-16 2007-05-16 Iap bir域结合化合物 Expired - Fee Related CN101535300B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US80041406P 2006-05-16 2006-05-16
US60/800,414 2006-05-16
US83377306P 2006-07-28 2006-07-28
US60/833,773 2006-07-28
US87935207P 2007-01-09 2007-01-09
US60/879,352 2007-01-09
PCT/CA2007/000887 WO2007131366A1 (en) 2006-05-16 2007-05-16 Iap bir domain binding compounds

Publications (2)

Publication Number Publication Date
CN101535300A CN101535300A (zh) 2009-09-16
CN101535300B true CN101535300B (zh) 2014-05-28

Family

ID=38693511

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780027024.4A Expired - Fee Related CN101535300B (zh) 2006-05-16 2007-05-16 Iap bir域结合化合物

Country Status (15)

Country Link
US (2) US8163792B2 (enExample)
EP (1) EP2024362A4 (enExample)
JP (1) JP5419685B2 (enExample)
KR (1) KR101506466B1 (enExample)
CN (1) CN101535300B (enExample)
AU (1) AU2007250443B2 (enExample)
BR (1) BRPI0711591A2 (enExample)
CA (1) CA2652455C (enExample)
IL (1) IL194871A (enExample)
MY (1) MY159563A (enExample)
NO (1) NO20084581L (enExample)
NZ (1) NZ572836A (enExample)
SG (2) SG10201407457UA (enExample)
WO (1) WO2007131366A1 (enExample)
ZA (1) ZA200809733B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005274937B2 (en) * 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
PL1851200T3 (pl) 2005-02-25 2014-06-30 Tetralogic Pharm Corp Dimeryczne inhibitory IAP
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
EP2049524A2 (en) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
WO2008014263A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
US20100113326A1 (en) * 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014229A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2156189A1 (en) * 2007-05-07 2010-02-24 Tetralogic Pharmaceuticals Corp. Tnf gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins
WO2008144925A1 (en) * 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2009155709A1 (en) * 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
SG172353A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
CN102459165B (zh) 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
CA2737601C (en) 2009-06-11 2014-10-21 Abbott Laboratories Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
EP2475254A4 (en) * 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2493879B1 (en) 2009-10-28 2014-05-14 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
WO2011068926A1 (en) * 2009-12-04 2011-06-09 Tetralogic Pharmaceuticals Corp. Iap inhibitors
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
EP2547333B1 (en) * 2010-03-18 2017-08-23 Innopharma, Inc. Stable bortezomib formulations
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
WO2014055461A1 (en) * 2012-10-02 2014-04-10 Bristol-Myers Squibb Company Iap antagonists
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
WO2019088270A1 (ja) * 2017-11-02 2019-05-09 宇部興産株式会社 蛋白分解酵素の双頭型阻害剤
JP7515175B2 (ja) 2018-07-31 2024-07-12 ファイメクス株式会社 複素環化合物
CN113453678A (zh) 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
WO2021020585A1 (ja) 2019-07-31 2021-02-04 ファイメクス株式会社 複素環化合物
CA3151770A1 (en) 2019-09-25 2021-04-01 Silvano BRIENZA Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1665784A (zh) * 2002-07-02 2005-09-07 诺瓦提斯公司 与细胞凋亡蛋白抑制剂结合的smac蛋白的肽抑制剂
CA2560162A1 (en) * 2004-04-07 2005-10-20 Novartis Ag Inhibitors of iap
WO2006122408A1 (en) * 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
WO2007048224A1 (en) * 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0680077B2 (ja) 1985-02-08 1994-10-12 サントリー株式会社 プロリンエンドペプチダ−ゼインヒビタ−活性を有する新規ペプチド化合物
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4939168A (en) 1989-08-11 1990-07-03 Harbor Branch Oceanographics Institution, Inc. Discodermolide compounds, compositions containing same and methods of preparation and use
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
JPH04208299A (ja) 1990-11-30 1992-07-29 Ajinomoto Co Inc プロリルエンドペプチターゼ阻害ペプチド
ATE190983T1 (de) 1991-08-09 2000-04-15 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate
US5990325A (en) 1993-03-05 1999-11-23 Florida State University Process for the preparation of 9-desoxotaxol, 9-desoxobaccatin III and analogs thereof
US5721268A (en) 1991-09-23 1998-02-24 Florida State University C7 taxane derivatives and pharmaceutical compositions containing them
US5399726A (en) 1993-01-29 1995-03-21 Florida State University Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups
US5728725A (en) 1991-09-23 1998-03-17 Florida State University C2 taxane derivaties and pharmaceutical compositions containing them
US6011056A (en) 1991-09-23 2000-01-04 Florida State University C9 taxane derivatives and pharmaceutical compositions containing them
US5714513A (en) 1991-09-23 1998-02-03 Florida State University C10 taxane derivatives and pharmaceutical compositions
IT1254515B (it) 1992-03-06 1995-09-25 Indena Spa Tassani di interesse oncologico, loro metodo di preparazione ed uso
US5831002A (en) 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
IT1261667B (it) 1993-05-20 1996-05-29 Tassano ad attivita' antitumorale.
US5952298A (en) 1993-12-21 1999-09-14 The University Of Hawaii Cryptophycins
US5955423A (en) 1993-12-21 1999-09-21 The University Of Hawaii Cryptophycins
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US6458976B1 (en) 1994-10-28 2002-10-01 The Research Foundation Of State University Of New York Taxoid anti-tumor agents, pharmaceutical compositions, and treatment methods
JPH10508022A (ja) 1994-10-28 1998-08-04 ザ リサーチ ファウンデーション オブ ステート ユニバーシティ オブ ニューヨーク タキソイド誘導体、それらの製造、およびそれらの抗腫瘍薬としての使用
US6500858B2 (en) 1994-10-28 2002-12-31 The Research Foundation Of The State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US6100411A (en) 1994-10-28 2000-08-08 The Research Foundation Of State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US5719177A (en) 1994-11-04 1998-02-17 Pharmacia S.P.A. Taxane derivatives
US5473057A (en) 1994-11-09 1995-12-05 The Regents Of The University Of California Eleutherobin and analogs thereof
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5580899A (en) 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
FI101923B (fi) 1995-12-05 1998-09-15 Nokia Telecommunications Oy Puheenvuorojen jakaminen suorakanavalla liikennöiville matkaviestimill e
US5767297A (en) 1997-02-05 1998-06-16 Ensuiko Sugar Refining Co., Ltd. Taxoid derivative and method of producing thereof
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
CZ297979B6 (cs) 1996-03-12 2007-05-16 Pg-Txl Company, L. P. Kompozice obsahující protinádorové lécivo konjugované s ve vode rozpustným polymerem, její pouzití pro výrobu léciva a implantovatelná lékarská pomucka
US6133437A (en) 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
IT1283633B1 (it) 1996-05-10 1998-04-23 Indena Spa Derivati tassanici loro sintesi e formulazioni che li contengono
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
AU710156B2 (en) 1996-07-15 1999-09-16 Kabushiki Kaisha Yakult Honsha Taxane derivatives and drugs containing the same
US5939527A (en) 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
US5741892A (en) 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
AU3740997A (en) 1996-08-26 1998-03-19 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
WO1998038192A1 (de) 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Seitenkettenmodifizierte epothilone
US5886025A (en) 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US5965537A (en) 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
FR2761990B1 (fr) 1997-04-10 1999-06-25 Pf Medicament Derives halogenes antimitotiques d'alcaloides de vinca
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6143721A (en) 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
JP2001512723A (ja) 1997-08-09 2001-08-28 シエーリング アクチエンゲゼルシヤフト 新規エポチロン誘導体、その製法およびその薬学的使用
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
DE69729128T2 (de) 1997-10-08 2005-04-28 Bio Research Corporation Of Yokohama, Yokohama Taxoid-derivate und verfahren zu ihrer herstellung
US5965718A (en) 1997-10-24 1999-10-12 The Scripps Research Institute Analogs of sarcodictyin and eleutherobin
AU758418B2 (en) 1997-12-19 2003-03-20 Kabushiki Kaisha Yakult Honsha Taxane derivatives
US6302838B1 (en) 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6258841B1 (en) 1998-06-29 2001-07-10 Parker Hughes Institute Tubulin binding compounds (COBRA)
US5985837A (en) 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6127406A (en) 1998-10-09 2000-10-03 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds and methods of use
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6433187B1 (en) 1998-12-17 2002-08-13 Tularik Inc. Certain polycyclic compounds useful as tubulin-binding agents
AU2795000A (en) 1998-12-22 2000-07-12 Novartis Ag Epothilone derivatives and their use as antitumor agents
AU3156700A (en) 1999-02-18 2000-09-04 Schering Aktiengesellschaft 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
SK287200B6 (sk) 1999-02-22 2010-03-08 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6414015B1 (en) 2000-01-28 2002-07-02 Utah State University Laulimalide microtubule stabilizing agents
US6576658B2 (en) 2000-02-24 2003-06-10 Harbor Branch Oceanographic Institution, Inc. Compositions and uses of dictyostatin compounds
PT1259502E (pt) 2000-03-01 2005-05-31 Harbor Branch Oceanographic Analogos biologicamente activos da discodermolida
US6362217B2 (en) 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US6489314B1 (en) 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
AU2001266583A1 (en) 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
US6624317B1 (en) 2000-09-25 2003-09-23 The University Of North Carolina At Chapel Hill Taxoid conjugates as antimitotic and antitumor agents
US7718600B2 (en) 2000-09-29 2010-05-18 The Trustees Of Princeton University IAP binding compounds
US6992063B2 (en) 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
US6670389B2 (en) 2001-02-09 2003-12-30 Kosan Biosciences, Inc. Laulimalide derivatives
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EP1368030A1 (en) 2001-02-20 2003-12-10 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US20030023082A1 (en) 2001-05-15 2003-01-30 Gary Ashley Epothilone derivatives and methods for making and using the same
WO2002098868A1 (en) 2001-06-01 2002-12-12 Bristol-Myers Squibb Company Epothilone derivatives
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
US20060258581A1 (en) 2001-11-21 2006-11-16 Reed John C Methods and composition for derepressions of IAP-inhibited caspase
WO2003045324A2 (en) 2001-11-26 2003-06-05 Kosan Biosciences, Inc. 14-methyl-epothilones
DE10164592A1 (de) 2001-12-21 2003-07-03 Schering Ag C1-C6-Epothilon-Fragmente und Verfahren für die Herstellung von C1-C6-Fragmenten von Epothilonen und deren Derivaten
WO2003074521A1 (en) 2002-03-01 2003-09-12 University Of Notre Dame Derivatives of epothilone b and d and synthesis thereof
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
JP2005530806A (ja) 2002-05-23 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
KR20090046973A (ko) 2002-11-27 2009-05-11 아이알엠 엘엘씨 암세포에서 세포자멸사를 유도하기 위한 방법 및 조성물
US20040180828A1 (en) 2003-01-30 2004-09-16 Yigong Shi Caspase-9 : BIR domain of XIAP complexes and methods of use
JP4315249B2 (ja) * 2003-02-07 2009-08-19 ジェネンテック・インコーポレーテッド アポトーシス亢進のための組成物と方法
US20100093645A1 (en) 2004-01-16 2010-04-15 Shaomeng Wang SMAC Peptidomimetics and the Uses Thereof
EP1723122B1 (en) 2004-03-01 2014-11-19 Board of Regents, The University of Texas System Dimeric small molecule potentiators of apoptosis
EP1740173A4 (en) 2004-03-23 2009-05-27 Genentech Inc AZABICYCLOOCTAN IAP INHIBITORS
PT1778718E (pt) 2004-07-02 2014-12-03 Genentech Inc Inibidores de iap
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
EA200700225A1 (ru) 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. Аналоги тетрапептида
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
PL1851200T3 (pl) 2005-02-25 2014-06-30 Tetralogic Pharm Corp Dimeryczne inhibitory IAP
US20070003535A1 (en) 2005-03-17 2007-01-04 Reed John C Methods and compositions for derepression of IAP-inhibited caspase
DE102005017116A1 (de) 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
AU2006254538A1 (en) 2005-05-25 2006-12-07 2Curex Aps Compounds modifying apoptosis
CN101193908B (zh) 2005-06-08 2012-04-11 诺瓦提斯公司 有机化合物
AU2006340014B2 (en) 2005-12-19 2012-12-20 Genentech, Inc. Inhibitors of IAP
BRPI0620058A2 (pt) 2005-12-20 2011-11-01 Novartis Ag combinação farmacêutica compreendendo compostos inibidores da ligação da proteìna smac a proteìnas inibidoras de apoptose, e um taxano, bem como uso da mesma
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
CA2646186A1 (en) 2006-03-21 2007-11-29 Joyant Pharmaceuticals, Inc. Small molecule apoptosis promoters
MX2008014140A (es) 2006-05-05 2009-01-19 Univ Michigan Mimeticos bivalentes de smac y los usos de los mismos.
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100113326A1 (en) 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100143499A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014229A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2049524A2 (en) 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
WO2008014263A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
CA2666112A1 (en) 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
US20100316573A1 (en) 2006-10-19 2010-12-16 Larry Alexander Gaither Organic Compounds
JP2010511057A (ja) 2006-11-28 2010-04-08 ノバルティス アーゲー 急性骨髄性白血病の処置のためのｉａｐ阻害剤の使用
EP2089024B1 (en) 2006-11-28 2011-05-18 Novartis AG Combination of iap inhibitors and flt3 inhibitors
US8058272B2 (en) 2006-12-07 2011-11-15 Novartis Ag Organic compounds
EP2125809A1 (en) 2006-12-19 2009-12-02 Genentech, Inc. Imidazopyridine inhibitors of iap

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1665784A (zh) * 2002-07-02 2005-09-07 诺瓦提斯公司 与细胞凋亡蛋白抑制剂结合的smac蛋白的肽抑制剂
CA2560162A1 (en) * 2004-04-07 2005-10-20 Novartis Ag Inhibitors of iap
WO2006122408A1 (en) * 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
WO2007048224A1 (en) * 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds

Also Published As

Publication number Publication date
IL194871A0 (en) 2009-08-03
EP2024362A1 (en) 2009-02-18
JP2009537461A (ja) 2009-10-29
CA2652455A1 (en) 2007-11-22
EP2024362A4 (en) 2012-01-25
MY159563A (en) 2017-01-13
BRPI0711591A2 (pt) 2011-11-16
US8163792B2 (en) 2012-04-24
NO20084581L (no) 2008-12-12
NZ572836A (en) 2011-12-22
WO2007131366A1 (en) 2007-11-22
US8648094B2 (en) 2014-02-11
AU2007250443A1 (en) 2007-11-22
CN101535300A (zh) 2009-09-16
CA2652455C (en) 2017-06-13
ZA200809733B (en) 2012-06-27
AU2007250443B2 (en) 2013-06-13
US20090192140A1 (en) 2009-07-30
US20120195915A1 (en) 2012-08-02
JP5419685B2 (ja) 2014-02-19
SG171682A1 (en) 2011-06-29
KR101506466B1 (ko) 2015-03-27
IL194871A (en) 2015-11-30
SG10201407457UA (en) 2014-12-30
KR20090010242A (ko) 2009-01-29

Similar Documents

Publication Publication Date Title
CN101535300B (zh) Iap bir域结合化合物
US7547724B2 (en) IAP BIR domain binding compounds
CA2607940C (en) Bir domain binding compounds
AU2007224932B2 (en) IAP BIR domain binding compounds
US20100203012A1 (en) Iap bir domain binding compounds
CN101443309B (zh) Iap bir域结合化合物
US20120141496A1 (en) Iap bir domain binding compounds
CN101360728A (zh) Iap bir结构域结合化合物
RU2472780C2 (ru) Соединения, связывающие домен bir белков iap
HK1124852A (en) Iap bir domain binding compounds
MX2008014502A (es) Compuestos de union a dominio de repeticion de proteinas inhibidoras de apoptosis baculovirales de las proteinas inhibidoras de apoptosis.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140528

Termination date: 20180516

CF01 Termination of patent right due to non-payment of annual fee